tetano
Editor, Senior Moderator
Am J Med
. 2022 Sep 28;S0002-9343(22)00637-4.
doi: 10.1016/j.amjmed.2022.08.019. Online ahead of print.
The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): Real-world experience at a large academic center
Mohanad M Al-Obaidi[SUP] 1 [/SUP], Ahmet B Gungor[SUP] 2 [/SUP], Sandra E Kurtin[SUP] 3 [/SUP], Ann E Mathias[SUP] 4 [/SUP], Bekir Tanriover[SUP] 5 [/SUP], Tirdad T Zangeneh[SUP] 6 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease (COVID-19) is associated with increased morbidity and mortality among immunocompromised patients. Tixagevimab-Cilgavimab (Tix-Cil) is a combination of two monoclonal antibodies approved for the prevention of COVID-19 complications in this high-risk group.
Methods: We retrospectively reviewed the charts of patients who received Tix-Cil during the Omicron variant period (January 17 to April 23, 2022), with a follow-up period until May 24, 2022. We collected data regarding patient underlying comorbidities and post Tix-Cil COVID-19 infections, deaths, and hospitalizations.
Results: There were 463 patients with a median age of 68, of which 51% were male, 79% White, 13.2% Hispanic, 1.7% Black/African American, and 5.8% who identified as Other. A total of 18% had undergone a solid organ transplantation (SOT) or Hematopoietic Stem Cell Transplantation (HSCT). Only 6/98 (6.1%) had a SARS-CoV-2 detected by PCR at a median 48 days (IQR 27.5, 69) follow-up. Forty-two patients (9.1%) were hospitalized, and four (0.9%) died, but none were attributed to COVID-19 or Tix-Cil. One hospitalized patient had an incidental, asymptomatic, positive SARS-CoV 2 by PCR. The median days from Tix-Cil administration to non-COVID-19 related hospitalization and death were 30 (IQR 17, 55) and 53 (IQR 18, 91), respectively.
Conclusion: Tix-Cil provides protection against COVID-19 complications in immunocompromised patients with suboptimal immune responses to vaccines.
Keywords: COVID-19; Immunocompromised Host; Tixagevimab–Cilgavimab.
. 2022 Sep 28;S0002-9343(22)00637-4.
doi: 10.1016/j.amjmed.2022.08.019. Online ahead of print.
The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): Real-world experience at a large academic center
Mohanad M Al-Obaidi[SUP] 1 [/SUP], Ahmet B Gungor[SUP] 2 [/SUP], Sandra E Kurtin[SUP] 3 [/SUP], Ann E Mathias[SUP] 4 [/SUP], Bekir Tanriover[SUP] 5 [/SUP], Tirdad T Zangeneh[SUP] 6 [/SUP]
Affiliations
- PMID: 36181789
- PMCID: PMC9519524
- DOI: 10.1016/j.amjmed.2022.08.019
Abstract
Background: Coronavirus disease (COVID-19) is associated with increased morbidity and mortality among immunocompromised patients. Tixagevimab-Cilgavimab (Tix-Cil) is a combination of two monoclonal antibodies approved for the prevention of COVID-19 complications in this high-risk group.
Methods: We retrospectively reviewed the charts of patients who received Tix-Cil during the Omicron variant period (January 17 to April 23, 2022), with a follow-up period until May 24, 2022. We collected data regarding patient underlying comorbidities and post Tix-Cil COVID-19 infections, deaths, and hospitalizations.
Results: There were 463 patients with a median age of 68, of which 51% were male, 79% White, 13.2% Hispanic, 1.7% Black/African American, and 5.8% who identified as Other. A total of 18% had undergone a solid organ transplantation (SOT) or Hematopoietic Stem Cell Transplantation (HSCT). Only 6/98 (6.1%) had a SARS-CoV-2 detected by PCR at a median 48 days (IQR 27.5, 69) follow-up. Forty-two patients (9.1%) were hospitalized, and four (0.9%) died, but none were attributed to COVID-19 or Tix-Cil. One hospitalized patient had an incidental, asymptomatic, positive SARS-CoV 2 by PCR. The median days from Tix-Cil administration to non-COVID-19 related hospitalization and death were 30 (IQR 17, 55) and 53 (IQR 18, 91), respectively.
Conclusion: Tix-Cil provides protection against COVID-19 complications in immunocompromised patients with suboptimal immune responses to vaccines.
Keywords: COVID-19; Immunocompromised Host; Tixagevimab–Cilgavimab.